Company: NIVFW
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001213900-25-033966
Chunk: 187

Company: NewGenIvf Group Ltd
Filing Date: 2025-04-22
Form: 20-F
Item: Item 19
Chunk 187
---
 financial statements.

On February 11, 2025, the
Company carried out a1-for-20reverse stock split of its issued and unissued shares. The effect of the reverse stock split was to consolidate
every 20 issued and unissued shares into one share.

On February 24, 2025, the
Company entered into a Consulting Services Agreement with A SPAC (Holdings) Group Corp (“ ASPAC”), pursuant to which the Company
engaged ASPAC for the provision of certain consulting services. It was agreed that the Company would provide consideration in the form
of cash and shares. On March 3, 2025, the Company issued the150,000Class A Ordinary Shares to ASPAC.

On February 27, 2025, the
Company received a confirmation from Nasdaq that its application to transfer its listing to the Nasdaq Capital Market had been approved
and that the Company’s securities were transferred to the Nasdaq Capital Market at the opening of business on February 28, 2025.
On March 10, 2025, the Company received a confirmation letter from Nasdaq confirming that it has demonstrated compliance with all of Nasdaq’s
listing requirements, including shareholder equity of more than $2.5m, as required in the Panel’s decision letter dated February
19, 2025

F-30

On February 28, 2025, the
Company completed its acquisition of the MicroSort technology from Genetics & IVF Institute, Inc. (“ GIVF”). Pursuant to
a Purchase Agreement dated January 21, 2025 between the Company and GIVF (“ Purchase Agreement”), the Company purchased all
of the Assets (as defined in the Purchase Agreement) and IP Licenses (as defined in the Purchase Agreement) relating to the MicroSort
technology from GIVF for a cash consideration of $750,000and a share consideration of125,000Ordinary Shares (“ MicroSort Acquisition”).
Under the terms of the agreement, the Company acquired the technology for US$5million, which was satisfied through a combination of US$750,000in cash and the issuance of2,500,000ordinary shares (as was adjusted to125,000ordinary shares after the Reverse Stock Split on February
11, 2025) at a deemed value of US$1.70per share.

On February 18, 2025, the
Company entered into a cooperation agreement with FERTILITY GROUP LLC (“ BOBCARE”) to